CRVO
CervoMed Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$28.33M
P/E Ratio
—
EPS
$-3.28
Beta
-4.47
52W High
$11.25
52W Low
$2.82
50-Day MA
$3.83
200-Day MA
$6.60
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $2.09M |
| Gross Profit (TTM) | $-20.02M |
| EBITDA | — |
| Operating Margin | -1489.00% |
| Return on Equity | -132.80% |
| Return on Assets | -72.40% |
| Revenue/Share (TTM) | $0.23 |
| Book Value | $1.15 |
| Price-to-Book | 2.66 |
| Price-to-Sales (TTM) | 13.56 |
| EV/Revenue | 307.67 |
| EV/EBITDA | 1.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.60% |
| Shares Outstanding | $9.26M |
| Float | $6.29M |
| % Insiders | 32.84% |
| % Institutions | 19.43% |
Historical Volatility
HV 10-Day
101.09%
HV 20-Day
76.43%
HV 30-Day
65.04%
HV 60-Day
70.52%
HV Rank
39.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($20.33 target)
8
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026